New chemoimmunotherapy combinations include 177Lu-DOTATATE, a somatostatin receptor-targeted radionuclide therapy, since SCLC is a neuroendocrine tumor, which expresses somatostatin receptors 55; BMS-986012, an anti-fucosyl-GM1 monoclonal antibody in a Phase 2 trial since fucosyl-GM1, a tumor-associated antigen, is highly expressed on SCLC cells but not on normal tissue; and LB-100, a small molecule inhibitor of protein phosphatase 2A (PP2A), which is overexpressed in SCLC. This evidence concerns the gene PTPA and small cell lung carcinoma.